Compare BioNTech SE - ADR (BNTX) vs e l f Beauty Inc (ELF) Price & Performance

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

ELF Beauty trades at $75.10, down 2.15% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.31 billion in 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights brand expansion and a 32% stock jump in June 2026, though growth is transitioning as the core brand softens.

The outlook is mixed: analyst consensus is evenly split between Buy and Hold, with a $74.42 price target near the current price. Upside potential exists from skincare and international expansion, but risks include cost pressures, tariff exposure, and the need to sustain double-digit sales growth amid competitive dynamics.